Skip to main content
. 2012 Feb 17;7(2):e31024. doi: 10.1371/journal.pone.0031024

Figure 5. Striatal DA and metabolites are affected at week 16 by Mn exposure and genotype.

Figure 5

A) There are no significant differences in striatal DA levels at week 13. B) There is no difference between striatal levels of DOPAC or HVA at week 13, however there is a significant main effect of genotype on ratio DOPAC/DA. The turnover rate of DA is significantly lower in YAC128-Mn than WT-Mn. C) At week 16 there is a significant effect of genotype and exposure on striatal DA levels. WT-Mn, YAC128-Veh and YAC128-Mn have lower levels of striatal DA than WT-Veh mice. D) There are also significant genotype and exposure effects on DA metabolites DOPAC and HVA at week 16. Levels of striatal DOPAC and HVA in WT-Mn, YAC128-Veh and YAC128-Mn are significantly lower than in WT-Veh mice. Monoamine neurotransmitter and metabolite means (week 13 n = 4–6 and week 16 n = 3–8) are graphed +/−SEM. Significance by post-hoc t-test *p<0.05, **p<0.01 and ##p<0.005.